Novo Nordisk Deploys $2.1 Billion Buyback as Oral Wegovy Prescriptions Explode and Medicare Looms
19.06.2026 - 13:47:21 | boerse-global.de
The Danish drugmaker’s stock jumped 4.36 percent to €39.25 on Wednesday, snapping a 50-day moving average at €37.00 and reigniting momentum in a name that has lost nearly 40 percent over the past twelve months. The rebound, however, masks a deep disconnect: while the market fixates on competitive threats from Eli Lilly and a revenue slowdown, Novo Nordisk is quietly shoving a fistful of catalysts onto the table — a record share buyback, a pill launch that is rewriting the prescription playbook, and a Medicare program poised to unlock millions of new patients.
Management has expanded its buyback program to as much as 15 billion Danish kroner — roughly $2.1 billion — a move designed to shore up earnings per share during a rocky transition. The capital return comes alongside a surge in uptake for oral Wegovy, the first FDA-approved GLP-1 pill for weight loss. Since its December 2025 debut, the drug has generated over two million prescriptions in the United States, with weekly volumes exceeding 200,000 by April. More than one million Americans started the medication in its first four months, and the company has already won approval from British regulators. The European Medicines Agency has recommended marketing authorization, with a launch outside the U.S. targeted for the second half of 2026.
Yet the stock’s 42 percent retreat from its 52-week high of €65.20 — and a 15.6 percent decline year-to-date — reflects a market that has priced in worst-case scenarios. The February stumble of CagriSema, a next-generation obesity candidate, dealt a heavy blow to confidence. In a head-to-head trial, patients lost 23 percent of their weight after 84 weeks, trailing the 25.5 percent achieved by Eli Lilly’s Zepbound. The market had expected equivalence, and the stock cratered 16 percent on the news. Novo Nordisk nonetheless submitted CagriSema to the FDA in December 2025, with a decision expected around the end of 2026. Notably, nearly 51 percent of participants in the study achieved a body mass index below 30.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The pessimism, however, may be overdone. The company’s pipeline — including oral Zenagamtide and the CagriSema filing — is underappreciated, and the most transformative near-term catalyst is flying under the radar. Starting in July 2026, a new Medicare Bridge program will provide eligible U.S. seniors access to Wegovy at a copay of $50 a month. Previously, Medicare did not cover weight-loss drugs. An estimated 3.4 million beneficiaries will qualify in the first six months alone, creating a massive new addressable market for Novo Nordisk, whose Wegovy carries the broadest label, including cardiovascular risk reduction.
The first-quarter results underscored both the opportunity and the headwinds. Revenue came in at 70.1 billion Danish kroner, a 4 percent decline year-on-year, but the oral Wegovy ramp offset weakness elsewhere. Management forecasts a currency-adjusted revenue and operating profit drop of between 4 and 12 percent for the full year 2026, a sobering outlook for investors accustomed to double-digit growth. Price pressure in the U.S. and Eli Lilly’s increasingly aggressive portfolio — Zepbound has superior efficacy — are forcing Novo Nordisk to compete on access and breadth rather than exclusive potency.
Valuation is beginning to reflect the scars. The stock trades 8.58 percent below its 200-day moving average of €41.23, and the 24.6 percent gap to its 52-week low of €30.25 suggests limited downside if the bear case is already discounted. The relative strength index sits at 51.2, signaling a market in equilibrium — neither panicked nor euphoric. For now, the buyback cushions the earnings hit, and the oral pill and Medicare expansion provide tangible demand drivers. But until the pipeline delivers margin-accretive new products, the shares remain hostage to the Eli Lilly narrative. The next chapter will be written in the second half of the year, when Medicare funding begins flowing and the EU launch adds a new revenue stream.
Ad
Novo Nordisk Stock: New Analysis - 19 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
